Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
Despite its Monsanto woes, Bayer is sticking with its diversified portfolio, and is branching out into patient-facing digital health services.
Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.
Pharma must “speak the same language” as the National Health Service for “transactable” negotiations.
Melanoma is first target for company developing cancer vaccines and T-cell receptor immunotherapies.
While bluebird bio, Celgene and GSK prepare to file, it’s time to shine for another myeloma contender.